Poxel SA: Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis
Source: finanznachrichten.de